scholarly journals FATTY LIVER DYSTROPHY MODELING BY USING STRONTIUM SULFATE

2021 ◽  
Author(s):  
Vladimir S. Ponamarev ◽  
Alexander M. Lunegov ◽  
Irina V. Lunegova ◽  
Victor A. Baryshev ◽  
Konstantin F. Zenkov
Keyword(s):  
Veterinary Medicine ◽  
Fatty Liver ◽  
Negative Impact ◽  
New Drugs ◽  
Hepatobiliary System ◽  
Strontium Sulfate ◽  
Pharmaceutical Activity ◽  
Hepatoprotective Agents

In recent years, the problem of the increasing number of the hepatobiliary system disorders has acquired particular importance for veterinary medicine. These disorders have negative impact on normal physiology of an animal's body. It is important to continue the search for effective hepatoprotective agents. To test the pharmaceutical activity of new drugs, methods of modeling hepatopathies are constantly being improved. The study suggested a model of fatty liver dystrophy using strontium sulfate.

New Drugs for Thromboembolic Prevention in Atrial Fibrillation

2010 ◽  
Vol 6 (4) ◽  
pp. 64
Author(s):  
Jose L Merino ◽  
Jose López-Sendón ◽  
◽  
Keyword(s):  
Atrial Fibrillation ◽  
Vitamin K ◽  
Negative Impact ◽  
Vitamin K Antagonists ◽  
Coagulation Factor ◽  
Developed Countries ◽  
New Drugs ◽  
Risk Scores ◽  
Bleeding Events ◽  
Risk Patients

Atrial fibrillation (AF) is the most frequent sustained arrhythmia and its prevalence is increasing in developed countries. This progressive increase and the negative impact of this arrhythmia on the patient’s prognosis make AF one of the main healthcare problems faced today. This has led to intense research into the main aspects of AF, one of them being thromboembolism prevention. AF patients have a four to five times higher risk of stroke than the general population. Several factors increase thromboembolic risk in patients with AF and the use of risk scores, such as the Congestive Heart Failure, Hypertension, Age Greater than 75, Diabetes, and Prior Stroke or Transient Ischemic Attack (CHADS2), have been used to identify the best candidates for anticoagulation. Antithrombotic drugs are the mainstay of therapy for embolic prevention. The clinical use of these drugs is based on the risk–benefit ratio, where benefit is the reduction of stroke and systemic embolic events and risk is mostly driven by the increase in bleeding events. Generally, antiplatelets are indicated for low-risk patients in light of the fact anticoagulants are the drug of choice for moderate- or high-risk patients. Vitamin K antagonists have been the only option for oral anticoagulation for the last 50 years. However, these drugs have many pharmacodynamic and pharmacokinetic problems. The problems of anticoagulation with vitamin K antagonists have led to the investigation of new drugs that can be administered orally and have a better dose–response relationship, a shorter half-life and, in particular, higher efficacy and safety without the need for frequent anticoagulation controls. The drugs that have been studied most thoroughly in patients with AF are inhibitors of the activated coagulation factor X and inhibitors of coagulation factor II (thrombin), including ximelagatran and dabigatran. In addition, non-pharmacological therapies have been developed to prevent recurrent embolism in certain patient populations.

OP157 Quo Vadis Romanian Health Technology Assessment?

2018 ◽  
Vol 34 (S1) ◽  
pp. 57-57
Author(s):  
Adrian Pana ◽  
Ioana Cristina Cosa
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Impact Analysis ◽  
Negative Impact ◽  
Health Technology ◽  
Evaluation Framework ◽  
New Drugs ◽  
Ministry Of Health ◽  
Healthcare Budget ◽  
Health Technologies

Introduction:The Romanian healthcare system has been struggling to use a more transparent approach in evaluating health care technologies for more than 10 years. No systemic and satisfactory approach to evaluate health technologies was implemented until the present. The objective of the presentation is to describe the characteristics of the HTA system used by the Romanian healthcare authority as well as the consequences of the drug assessments by using the actual Romanian health technology assessment (HTA) evaluation framework, from the initiation in May 2014 to the end of year 2017.Methods:The drug reimbursement context and the healthcare legislation regarding HTA evaluation were studied. A critical appraisal of the scorecard was conducted, taking into consideration general principles of the health technology assessment. A descriptive analysis covering the assessment drug reports issued by the National Agency for Drug and Medical Devices (NADMD) issued between May 2014 and December 2017 was presented, together with the decision made by the Ministry of Health and the Romanian government.Results:During the analyzed period of time, more than 10 updates of the reimbursement list were implemented by the Ministry of Health. By November 2017, more than 180 drugs (new INN, new indications or fix dose combinations) were included in the reimbursement system with conditional or unconditional reimbursement; more than 230 reports were assessed by the NADMD. While the new drugs reimbursed between May 2014 and November 2017, in the most part demonstrated cost savings, a lot of new innovative drugs proposed to be evaluated were rejected since the drugs had no comparators on the Romanian market and their costs were considered to have a negative impact on the healthcare budget.Conclusions:The rapid HTA assessment has many strengths, by using a proper scorecard. Limitations and weakness of the actual scorecard were identified, mainly regarding the lack of a basic budget impact analysis which must include at least the direct healthcare cost, as well as the imported results of different healthcare environments that are not matching the Romanian context. Opportunities to implement a more rapid and accurate HTA evaluation are identified since the scorecard could be updated in order to address the HTA general principles.

scholarly journals Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Péter Jenő Hegyi ◽  
Szilárd Váncsa ◽  
Klementina Ocskay ◽  
Fanni Dembrovszky ◽  
Szabolcs Kiss ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Negative Impact ◽  
Meta Analysis ◽  
Severe Disease ◽  
Close Monitoring ◽  
Alcoholic Fatty Liver ◽  
Icu Admission ◽  
Increased Risk

Background: The most common pre-existing liver disease, the metabolic dysfunction-associated fatty liver disease (MAFLD) formerly named as non-alcoholic fatty liver disease (NAFLD), may have a negative impact on the severity of COVID-19. This meta-analysis aimed to evaluate if MAFLD or NAFLD are associated with a more severe disease course of COVID-19.Methods: A systematic search was performed in five databases for studies comparing severity, the rate of intensive care unit (ICU) admission, and mortality of COVID-19 patients with and without MAFLD or NAFLD. In meta-analysis, pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.Results: Altogether, we included nine studies in our quantitative and qualitative synthesis. MAFLD was associated with an increased risk of severe COVID-19 compared to the non-MAFLD group (28 vs. 13%, respectively; OR = 2.61, CI: 1.75–3.91). Similarly, in the NAFLD vs. non-NAFLD comparison, NAFLD proved to be a risk factor as well (36 vs. 12%, respectively; OR = 5.22, CI: 1.94–14.03). On the other hand, NAFLD was not associated with an increased risk of ICU admission (24 vs. 7%, respectively; OR = 2.29, CI: 0.79–6.63). We were unable to perform meta-analysis to investigate the association of MAFLD with the rate of ICU admission and with mortality.Conclusion: In conclusion, patients with MAFLD and NAFLD showed a more severe clinical picture in COVID-19. Our results support the importance of close monitoring of COVID-19 patients with MAFLD. Further research is needed to explore the cause of increased severity of COVID-19 in MAFLD.

Перспективные препараты для инкрустирования семян столовых корнеплодов

2018 ◽  
Author(s):  
Yu.A. Bykovskii ◽  
A  Yanchenko ◽  
M  Azopkov ◽  
V  Golubovich ◽  
S  Fefelova ◽  
...  
Keyword(s):  
Growth Regulators ◽  
Field Experiments ◽  
Plant Density ◽  
Negative Impact ◽  
Positive Impact ◽  
New Drugs ◽  
Agricultural Crops ◽  
Organic Complex ◽  
Germination Energy ◽  
Germination Experiments

Цель исследований: оценка эффективности инкрустирования семян столовых корнеплодов рядом новых препаратов, его влияния на посевные качества: энергию прорастания, лабораторную всхожесть, полевую всхожесть. Опыты проводили лабораторных и полевых условиях в Быковском расширении Москворецкой поймы (Раменский район Московской области) по стандартным методикам: ГОСТ 120036–85 «Семена сельскохозяйственных культур. Правила приемки и методы отбора проб», ГОСТ 12038–84 «Семена сельскохозяйственных культур. Методы определения всхожести». Посевные качества оценивали по ГОСТ 32917–2014 «Семена овощных культур и кормовой свеклы дражированные. Посевные качества. Общие технические условия». Лабораторно-полевые опыты проводили по методикам, изложенным в книге «Методика опытного дела в овощеводстве и бахчеводстве» под редакцией С.С. Литвинова. В качестве кремнеауксиновых регуляторов роста использованы препараты Энергия-М (в качестве стандарта), Энербат, Силабат, ОКМ (органический комплекс меди), Крезабат. В результате исследований были получены экспериментальные данные о том, что включение новых кремнеауксиновых регуляторов роста в оболочку дражированных семян моркови столовой неодинаково влияет на их всхожесть и густоту стояния растений. Использование препарата Крезабат отрицательно сказалось на урожайности столовой моркови и ее сохраняемости. Включение в состав оболочки дражированных семян столовой моркови кремнеауксиновых препаратов незадолго до посева не снижает посевных качеств семян: энергии прорастания и лабораторной всхожести, но увеличивает полевую всхожесть. Применение препаратов Энербат и ОКМ (органический комплекс меди) положительно сказалось на сохраняемости посевов столовой моркови. Наибольшая прибавка стандартных корнеплодов была получена в варианте с применением препарата Энербат. Однако существенную прибавку по отношению к контролю дали также варианты Силабат и ОКМ.The purpose of the research: to evaluate the effectiveness of seed root crops encrusting with a number of new drugs, its impact on the sowing qualities: germination energy, laboratory germination, field germination. Experiments were carried out under laboratory and field conditions in the Bykovo expansion of Moscow river floodplain (Ramensky district, Moscow region) according to standard methods: GOST 120036–85: Seeds of agricultural crops. Acceptance rules and sampling methods, GOST 12038–84: Seeds of agricultural crops. Methods for determination of germination. Sowing qualities were assessed according to GOST 32917–2014: Vegetable seeds and fodder beet pelleted seeds. Sowing qualities. General specifications. Laboratory field experiments were carried out according to the methods described in the «Methods of experimental work in vegetable and melon production» edited by S. Litvinov. As growth regulators preparations Energia-M (as standard), Enerbat, Silabat, OKM (organic complex of copper), Crezabat were used. As a result of the research was experimental evidence that the inclusion of new growth regulators in the shell pelleted seeds carrot unequally affects germination and plant density. The use of the Krezabat preparation had a negative impact on the yield of carrot and its persistence. The inclusion in the composition of the shell pelleted seeds of carrot silicon auxin preparations shortly before seeding did not reduce sowing qualities of seeds: germination energy and laboratory germination, but increases germination. The use of Enerbat and OKM (organic complex of copper) preparations had a positive impact on the persistence of the crops of carrot. The greatest rise in standard of roots was obtained in the variant with use of the Enerbat preparations. However, a significant increase relative to the control were also options Silabat and OKM.

scholarly journals The Development of Phyto- and Tissue Origin Medicines for Veterinary Reproductive Issues

2021 ◽  
Vol 24 (8) ◽  
pp. 15-25
Author(s):  
Pavlo Skliarov ◽  
Serhiy Fedorenko ◽  
Svitlana Naumenko ◽  
Vsevolod Koshevoy ◽  
Kateryna Pelyh
Keyword(s):  
Veterinary Medicine ◽  
High Efficiency ◽  
Sperm Quality ◽  
Reproductive Function ◽  
The Body ◽  
Growth Potential ◽  
New Drugs ◽  
Reproductive Capacity ◽  
Treatment And Prevention ◽  
Tissue Origin

Modern conditions of practical veterinary medicine require the use of effective and safe drugs. Along with the already known and common medicines, the search for new drugs which are harmless for the body and have the physiological direction of action is still required. In recent years, the attention to the use of phyto- and tissue-derived drugs increased. However, the problem of their use is insufficiently studied – many aspects of their clinical use require further development, expansion of the spectrum of used medicinal plants, study, and implementation into veterinary practice. Therefore, the purpose of this work was to develop a comprehensive vitamin-hormone drugs based on phyto- and tissue medicines for the treatment and prevention of reproductive abnormalities in animals. Based on the information on the etiopathogenesis of disorders of reproductive function indicators: homeostasis, reducing of the concentration of hormones (estrogen or progesterone), changes in the morphofunctional state of endocrine (pituitary, thyroid, and adrenal gland) and reproductive (ovaries) organs, the application of vitamin-hormone drugs in veterinary medicine is scientifically sound. Drugs in terms of pathogenetic therapy can optimise homeostasis, hormone concentrations, stimulate rehabilitation processes in the regulatory organs of reproductive function (pituitary, adrenal, and thyroid) and reproductive organs (ovaries), which, in turn, contributes to the normalisation of follicles which are a prerequisite for the full reproductive capacity of females. Vitamin-hormonal medicines of herbal and tissue origin were developed, with high efficiency for the treatment and prevention of reproductive pathologies of various species of animals, providing the stimulation of reproductive function (estrus signs) for therapy of females with gonadopathies (“Carafest”, “Caplaestrol” and “Caplagonìn”) and males (display of sexual reflexes and sperm quality) for reproductive activity dysfunction (“Carafand”), increase in the viability of the newborn (increasing the number of lambs and goatlings with satisfactory clinical condition with a high-growth potential, reduce in their morbidity and lethality), preventing the incidence of ìntra- and postnatal (labor hypofunction, diseases of post-labor period) pathology (“Carafest”, and “Caplaestrol”)

scholarly journals RECOMMENDATIONS FOR THE DESCRIPTION OF VETERINARY CLINICAL CASES

2020 ◽  
pp. 5-10
Author(s):  
С.В. АКЧУРИН ◽  
Г.П. ДЮЛЬГЕР ◽  
И.В. АКЧУРИНА ◽  
В.С. БЫЧКОВ ◽  
Е.С. ЛАТЫНИНА
Keyword(s):  
Veterinary Medicine ◽  
Negative Impact ◽  
Veterinary Services ◽  
Case Discussion ◽  
Veterinary Students ◽  
Contact Information ◽  
Teachers And Students ◽  
Number Of Publications ◽  
Clinical Cases

Проблема и цель. Проблемой в системе высшего ветеринарного образования является дефицит ветеринарных клинических кейсов на русском языке, находящихся в свободном доступе, что оказывает негативное влияние на процесс непрерывного повышения качества подготовки студентов ветеринарных специальностей и повышения квалификации практикующих врачей. Библиометрический анализ публикаций, проведенный по материалам библиотеки eLIBRARY, позволил установить, что доля работ, посвященных использованию кейсов в ветеринарии, в общем количестве публикаций на тему кейсов составляет всего 0,04 %. Целью настоящего исследования является создание рекомендаций по разработке ветеринарных клинических кейсов. Методология. На основании результатов анализа отечественной и зарубежной литературы, в первую очередь, ветеринарного и медицинского профилей, личной практики авторов ими разработаны и представлены рекомендации по составлению ветеринарных клинических кейсов. Результаты. В результате проведенных исследований предложена структура ветеринарного клинического кейса, который включает в себя 12 разделов (заголовок, контактная информация, ключевые слова, аннотация, введение, кейс, обсуждение кейса, благодарности, ссылки, приложение, разрешения, конфликт интересов) и содержит рекомендации по написанию каждого из разделов. Разработанные рекомендации предлагают практикующим ветеринарным врачам, исследователям, преподавателям и студентам готовую структуру для написания и публикации кейсов, что будет способствовать увеличению числа публикуемых случаев из практики. Заключение. Большое количество и доступность качественных и актуальных кейсов в области ветеринарии, безусловно, будет способствовать повышению квалификации ветеринарных кадров, а, следовательно, и росту качества оказания ветеринарных услуг населению. Ключевые слова: кейс, кейс-метод, структура кейса, ветеринарная медицина, образование. Timiryazev Problem and purpose. A problem in the system of higher veterinary education is the lack of freely available veterinary clinical cases in Russian, which has a negative impact on the process of continuous improvement of the quality of training veterinary students and advanced training of practicing doctors. The bibliometric analysis of publications based on eLIBRARY made it possible to establish that the share of works devoted to the use of cases in veterinary medicine in the total number of publications on cases is only 0.04 %. The purpose of this study is to create recommendations for the development of veterinary clinical cases. Methodology. Based on the results of the analysis of domestic and foreign literature of primarily veterinary and medical profles, and personal practice of the authors, recommendations were developed to prepare veterinary clinical cases. Results. As a result of the research, the structure of the veterinary clinical case is proposed, which includes 12 sections (title, contact information, key words, abstract, introduction, case, case discussion, acknowledgments, links, appendix, permissions, confict of interest) and contains recommendations for writing each of the sections. The developed guidelines ofer practicing veterinarians, researchers, teachers and students a readymade structure for writing and publishing cases, which will contribute to an increase in the number of published cases from practice. Conclusion. At the same time, a large number and availability of high-quality and relevant cases in the feld of veterinary medicine will undoubtedly contribute to an increase in the qualifcations of veterinary personnel, and, consequently, the quality of veterinary services to the population

scholarly journals Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology

2020 ◽  
Vol 26 (4) ◽  
pp. 461-475
Author(s):  
Silvia Sookoian ◽  
Carlos J. Pirola
Keyword(s):  
Liver Disease ◽  
Systems Biology ◽  
Fatty Liver ◽  
Precision Medicine ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
New Drugs ◽  
Polygenic Risk Score ◽  
Accurate Identification ◽  
Nonalcoholic Fatty Liver

Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and developments in precision medicine with a particular focus on new potential therapeutic discoveries modeled via systems biology approaches. In addition, we computed and simulated the potential utility of the NAFLD polygenic risk score, which could be conceptually very advantageous not only for early disease detection but also for implementing actionable measures. Incomplete knowledge of the druggable NAFLD genome severely impedes the drug discovery process and limits the likelihood of identifying robust and safe drug candidates. Thus, we close this article with some insights into emerging disciplines, such as chemical genetics, that may accelerate accurate identification of the druggable NAFLD genome/proteome.

scholarly journals Hepatobiliary system diseases as the predictors of psoriasis progression

2016 ◽  
Vol 71 (2) ◽  
pp. 102-108 ◽  
Author(s):  
Svetlana Vital'evna Smirnova ◽  
Anna Aleksandrovna Barilo ◽  
Marina Viktorovna Smol'nikova
Keyword(s):  
Psoriatic Arthritis ◽  
Fatty Liver ◽  
Clinical Stage ◽  
Chronic Cholecystitis ◽  
Excess Body Weight ◽  
Gamma Glutamyl Transferase ◽  
Alcoholic Fatty Liver ◽  
Psoriatic Disease ◽  
Hepatobiliary System ◽  
Glutamyl Transferase

Purpose of the study. To assess the state of the hepatobiliary system in psoriasis and psoriatic arthritis in order to establish a causal relationship and to identify clinical and functional predictors of psoriatic disease progression.Methods. The study included patients with extensive psoriasis vulgaris (n = 175) from the age of 18 to 66. Divided into 3 groups: 1 – psoriasis patients with isolated skin lesions (n = 77), 2 – patients with psoriatic arthritis (n = 98), 3 – apparently healthy blood donors (n = 30), matched by sex and age. The evaluation of functional state of the hepatobiliary system was performed by analysis of the clinical and anamnestic data and by the laboratory- instrumental methods.Results. Identified predictors psoriasis: triggers (stress and nutritional factor),  increased total bilirubin, aspartate aminotransferase, alkaline phosphatase, gamma glutamyl transferase, eosinophilia, giardiasis, carriers of hepatitis C virus, and changes focal ductal formation in the liver , thickening of the walls of the gallbladder by ultrasound. Predictors of psoriatic arthritis: age over 50 years, dyspeptic complaints, the presence of hepatobiliary system diseases, the positive right hypochondrium syndrome, the clinical symptoms of chronic cholecystitis, excess body weight, high  levels of bilirubin, cholesterol and low density lipoprotein, hepatomegaly, non-alcoholic fatty liver disease.Conclusion. High activity of hepatocytes cytolysis, cholestasis, inflammation, metabolic disorders can be considered psoriatic arthritis as a severe clinical stage psoriatic disease where the hepatobiliary system, in turn, is one of the main target organs in systemic psoriatic process. Non-alcoholic fatty liver disease and chronic cholecystitis are predictors of psoriatic disease progression.

scholarly journals Antibiotics in the environment: status and problems

2021 ◽  
Vol 6 (3) ◽  
pp. 251-265
Author(s):  
S. S. Timofeeva ◽  
O. S. Gudilova
Keyword(s):  
Antibiotic Resistance ◽  
Veterinary Medicine ◽  
Human Health ◽  
Negative Impact ◽  
Ecological Rehabilitation ◽  
Foreign Literature ◽  
Environmental Objects ◽  
The World ◽  
Many Sources ◽  
Modern Technologies

Scientists all over the world are working on the problem of pollution of environmental objects with antibiotics, which entails serious consequences for human health. The aim of the study is to review domestic and foreign literature data on the distribution of antibiotics in environmental objects and the sources of their formation. A negative impact on humans was noted due to the uncontrolled intake of antibiotics into the environment. In the world, even before the outbreak of the COVID-19 coronavirus pandemic, there was an extremely serious problem in the form of antibiotic resistance of microorganisms. The analysis showed that there are many sources of antibiotics entering the environment: they are widely used not only in medicine, but also in veterinary medicine and agriculture. It is concluded that modern technologies for the ecological rehabilitation of contaminated areas and a change in legislation are needed to change the situation towards improving safety.

Maintenance Treatment after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Multiple Myeloma (MM) with a Unique Weekly Dose of Pegylated Interpheron alpha2b (Pegintron®): Preliminary Clinical Results in 30 Patients of a Phase II Multicentric Study.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4822-4822
Author(s):  
Adrian Alegre ◽  
B. Aguado ◽  
J. Garcia-Laraña ◽  
J.J. Lahuerta ◽  
M.V. Mateos ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Phase Ii ◽  
Maintenance Treatment ◽  
Low Dose ◽  
Negative Impact ◽  
New Drugs ◽  
Weekly Dose ◽  
Multicentric Study ◽  
Autologous Pbsct ◽  
New Formulation

Abstract Introduction Intensification therapy in MM with autologous PBSCT is widely indicated for younger patients with favourable results regarding response, OS and PFS. However, there is no clear plateau in the survival curve. To improve these results and to prolong remission duration, various maintenance treatments have been proposed. Interpheron alpha2b s.c, at low dose, steroids on alternate days and most recently, low dose oral thalidomide, have demonstrated improvements in EFS and OS times but these results needs confirmation. Recently a new formulation of interpheron alpha2b (Pegintron®) is available conjugated with polietilenglicol with the advantage of being administered on a unique weekly dose. This new formulation of Interpheron alpha has been tested scarcely in MM. We present the preliminary results of a spanish, phase II, non comparative, multicentric study (PI-MM-01) with Pegintron® (Schering-Plough) as maintenance treatment after autologous PBSCT. Patients y Methods From May 2003 to March 2007, 30 patients were included in this study, 64% female and 36% male, with a median 56 years, received Pegintron® once a week subcutaneously as maintenance treatment after favourable response post-HDT with autologous PBSCT when the engraftement was stable and complete. The initial dose was 15 mg/week × 2 week and this dose was escalated to 25 mg/week and then 35 mg/week. The final dose was adopted according clinical and hematological tolerance. The maintenance treatment was continued at least 5 years postransplant or until toxicity, relapse or progressión. Results 30 patients were evaluable for this preliminary analysis. The median time from transplant to IFN treatment was 3.8m. The median dose of Pegintron was 15 mg/week. 9 patients have suspended the treatment (30%). 5 cases (16%) due to progression, 2 (4%) for toxicity and 2(4%) for other reason. The remainder 21 patients (76%) continue the treatment with clinical response, with median duration of 16 months (2–42). At present all patients are alive. Astenia, “pseudo-flu” symptoms and thrombopenia and neutropenia were the most common adverse effects observed, that limited the dose escalation, being 15 mg/week the best tolerated and mos frequent dose (70%). One patient suspended the treatment due to dermatological reaction with pruritus. Conclusions and Comments Although these results need completion and further analysis, maintenance treatment with a weekly dose of Interpheron-a2b conjugated with Polietilenglicol (Pegintron®) is well tolerated after autologous PBSCT in MM. No major adverse effects were observed and no relevant negative impact was observed on the autologous graft. Pegintron® sc could be an alternative to standard interpheron sc with the main advantage of therapy simplification with only one dose weekly. More experiences and longer follow up are needed to evaluate the role of this strategy in the global treatment of MM and new approaches for maintenance have to be investigated, including association and comparison with steroids or new drugs as thalidomide, bortezomib or lenalidomide.

Sign in / Sign up

Export Citation Format

Share Document